Literature DB >> 1362531

The three week sulphasalazine syndrome.

H Brooks1, H G Taylor, F E Nichol.   

Abstract

We report a 53-year-old man with sero-negative rheumatoid arthritis who developed a fever, rash and hepatitis 3 weeks after starting sulphasalazine therapy. This was associated with a T cell lymphocytosis, eosinophilia and evidence of classical complement pathway activation. He responded to high dose corticosteroids. This is a rare but characteristic reaction which is likely to be encountered by rheumatologists more frequently with the increasing use of sulphasalazine. It should be recognized promptly as it may be fatal and can be confused with other systemic diseases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362531     DOI: 10.1007/bf02283121

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  16 in total

1.  Sulphasalazine induced autoimmune syndrome.

Authors:  T Vyse; A K So
Journal:  Br J Rheumatol       Date:  1992-02

2.  Severe immunological reaction induced by sulphasalazine.

Authors:  T Pettersson; M Gripenberg; G Molander; C Friman
Journal:  Br J Rheumatol       Date:  1990-06

3.  Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: results of a co-operating clinics study.

Authors:  S Donovan; S Hawley; J MacCarthy; D L Scott
Journal:  Br J Rheumatol       Date:  1990-06

4.  Sulfasalazine toxic reactions. Hepatitis, fever, and skin rash with hypocomplementemia and immune complexes.

Authors:  A A Mihas; D J Goldenberg; R L Slaughter
Journal:  JAMA       Date:  1978-06-16       Impact factor: 56.272

5.  Glandular fever-like illness associated with sulphasalazine.

Authors:  D L Carr-Locke; M Ali
Journal:  Postgrad Med J       Date:  1982-10       Impact factor: 2.401

6.  Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats.

Authors:  K M Das; J R Chowdhury; B Zapp; J W Fara
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

7.  Serious complications of sulfasalazine.

Authors:  R K Pearl; R L Nelson; M L Prasad; C P Orsay; H Abcarian
Journal:  Dis Colon Rectum       Date:  1986-03       Impact factor: 4.585

8.  Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine.

Authors:  J Ribe; K J Benkov; S N Thung; S C Shen; N S LeLeiko
Journal:  Am J Gastroenterol       Date:  1986-03       Impact factor: 10.864

9.  Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis.

Authors:  D Caspi; D Fuchs; M Yaron
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

10.  Experimental glomerulonephritis. The pathogenesis of a laboratory model resembling the spectrum of human glomerulonephritis.

Authors:  F J DIXON; J D FELDMAN; J J VAZQUEZ
Journal:  J Exp Med       Date:  1961-05-01       Impact factor: 14.307

View more
  5 in total

1.  Favourable issue of a fulminant hepatitis associated with sulfasalazine DRESS syndrome without liver transplantation.

Authors:  Elodie Descloux; Laurent Argaud; Jérôme Dumortier; Jean-Yves Scoazec; Olivier Boillot; Dominique Robert
Journal:  Intensive Care Med       Date:  2005-11-10       Impact factor: 17.440

2.  Sulphasalazine in the treatment of pauciarticular-onset juvenile chronic arthritis.

Authors:  A Gedalia; J Barash; J Press; D Buskila
Journal:  Clin Rheumatol       Date:  1993-12       Impact factor: 2.980

3.  Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis.

Authors:  L G Quallich; J Greenson; H M Haftel; R J Fontana
Journal:  BMC Gastroenterol       Date:  2001-08-29       Impact factor: 3.067

4.  Drug hypersensitivity syndrome induced by sulfasalazine: A case report.

Authors:  Dong-Hui Chen; Hai-Rong Zhou; Yong-Gang Zhang; Guan-Yuan Shen; Chong Xu; Chun-Li Guan
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

5.  Case of relapsing sulfasalazine-induced hypersensitivity syndrome upon re-exposure.

Authors:  Jason Winward; Laurel Lyckholm; Samuel M Brown; Mohamad Mokadem
Journal:  BMJ Case Rep       Date:  2020-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.